Kent, United Kingdom

Neti Fraser Fairweather


Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 1999

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Neti Fraser Fairweather: Innovator in Vaccines Against Bordetella

Introduction: Neti Fraser Fairweather, an esteemed inventor based in Kent, GB, has made significant contributions to the field of immunology. His innovative work primarily focuses on developing polypeptides for vaccines aimed at combating Bordetella pertussis, a bacterium responsible for whooping cough.

Latest Patents: Fairweather holds a notable patent titled "Polypeptides and vaccines for Bordetella pertussis and method of use." This patent describes a specific polypeptide designed for use in a vaccine against Bordetella pertussis, Bordetella parapertussis, or Bordetella bronchiseptica. The polypeptide is characterized by an epitope derived from the amino acid sequence coded for by nucleotides 1885 to 1902 of the P.69 gene of strain CN2992. Additionally, the patent includes a chimaeric protein composed of a carrier protein and a sequence containing the essential epitope, ensuring it can be no longer than 50 amino acid residues.

Career Highlights: Neti Fraser Fairweather is associated with Medeva Pharma Limited, where he applies his expertise in developing vital immunological solutions. His groundbreaking research and commitment to advancing vaccine technology have positioned him as a key figure in the pharmaceutical industry.

Collaborations: Fairweather collaborates with Ian George Charles, leveraging their combined knowledge and skills to enhance the development of innovative vaccines. Their partnership underscores the importance of teamwork in driving forward groundbreaking medical advancements.

Conclusion: Neti Fraser Fairweather's contributions, exemplified by his patent for a vaccine targeting Bordetella species, highlight the significance of innovation in the realm of medicine. His ongoing work at Medeva Pharma Limited, alongside collaborators like Ian George Charles, continues to impact public health through the development of effective immunological therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…